首页> 外国专利> New fused thieno:imidazole derivs. as angiotensin II antagonists - for treating hypertonia, coronary insufficiency, angina pectoris anarteriosclerosis

New fused thieno:imidazole derivs. as angiotensin II antagonists - for treating hypertonia, coronary insufficiency, angina pectoris anarteriosclerosis

机译:新的稠合噻吩并咪唑衍生物。作为血管紧张素II拮抗剂-用于治疗高渗,冠状动脉供血不足,心绞痛,动脉粥样硬化

摘要

Thienoimidazole derivs. of formula (I) and their acid and base addn. salts are new. In (I) A is a gp. of formula (a), (b) or (c). In (a)-(c) R1 is H, 1-8C alkyl, 3-6C alkenyl, 3-6C alkynyl (these last 3 gps. opt. substd. with a halogen or OR5 gp. or with one or two CO2R5 gps.), 3-6C cycloalkyl, 1-4C perfluoroalkyl, di(1-4C)alkylamino, or benzyl; R2 = a gp. of formula (d)-(k); B is formula (III). B = -(CH2)M-, CR16R17, -CR16R17CH2-, -CH2CR16R17-, or C=CR18R19; R3 and R4 = each H, F, Cl, Br 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, 1-6C perfluoroalkyl, 3-6C cycloalkyl, 1-4C alkoxy or CN, C6F5 etc. R7 = 1-4C alkyl or benzyl; R8 and R9 = each H, 1-4C alkyl, Ph, benzyl or together with an N form a ring of formula (l). R10 = H, 1-4C alkyl, benzyl or 1-6C alkanoyl. R13 = CO2R5, NHSO2R2O, R14 and R15 are each H, F, Cl, Br, CN, OR5, 1-4C alkyl, 2-4C alkenyl, 2-4C alkynyl, NO2, NH2, 1-4C alkylamino, di(1-4C alkyl) amino, 1-4C alkanoyl, R16 and R17 = each H, 1-4C alkyl, 3-4C alkenyl, 3-4C alkynyl or -CH2-CH"-; R18 and R19 = each H, 1-4C alkyl or -CH2)r- R20 = 1-6C alkyl or 1-6C perfluoroalkyl; T = -CH2-, -O- or -NR10-; P = 3-4; and r = 4-5. USE/ADVANTAGE - (I) are competitive angiotensin (II) antagonists which bond to angiotensin II receptors with high affinity and inhibit angiotensin II induced effects both in vivo and in vitro. (I) can be used in the treatment of eg. hypertonia. cardiac insufficiency, angina pectoris and antericosclerosis. Suitable doses are 0.01-50 mg/kg.
机译:噻吩并咪唑衍生物。式(I)的通式及其酸和碱加成基。盐是新的。在(I)中,A为gp。式(a),(b)或(c)的化合物。在(a)-(c)中,R1是H,1-8C烷基,3-6C烯基,3-6C炔基(最后3 gps。可选用卤素或OR5 gp。或一个或两个CO2R5 gps 。),3-6C环烷基,1-4C全氟烷基,二(1-4C)烷基氨基或苄基; R2 = gp。式(d)-(k); B是式(III)。 B =-(CH2)M-,CR16R17,-CR16R17CH2-,-CH2CR16R17-或C = CR18R19; R3和R4分别为H,F,Cl,Br 1-6C烷基,2-6C烯基,2-6C炔基,1-6C全氟烷基,3-6C环烷基,1-4C烷氧基或CN,C6F5等.R7 = 1 -4C烷基或苄基; R 8和R 9 =每个H,1-4C烷基,Ph,苄基或与N一起形成式(1)的环。 R10 = H,1-4C烷基,苄基或1-6C烷酰基。 R 13 = CO 2 R 5,NHSO 2 R 2 O,R 14和R 15分别为H,F,Cl,Br,CN,OR5、1-4C烷基,2-4C烯基,2-4C炔基,NO2,NH2、1-4C烷基氨基,二(1 -4C烷基)氨基,1-4C烷酰基,R16和R17 =每个H,1-4C烷基,3-4C烯基,3-4C炔基或-CH2-CH“-; R18和R19 =各个H,1-4C烷基或-CH2)r- R20 = 1-6C烷基或1-6C全氟烷基; T = -CH2-,-O-或-NR10-; P = 3-4; r = 4-5。使用/优点- (I)是竞争性血管紧张素(II)拮抗剂,它们以高亲和力与血管紧张素II受体结合并在体内和体外均抑制血管紧张素II诱导的作用(I)可用于治疗例如高渗,心脏功能不全,心绞痛胸大肌和动脉硬化,合适的剂量为0.01-50 mg / kg。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号